Loading
companiesCompany
Mabion
Mabion is a Polish biotech near Łódź that developed a rituximab biosimilar, MabionCD20, through phase 3 trials in lymphoma and rheumatoid arthritis, and now also manufactures biologics for partners.
Also called: Mabion SAMabion S.A.
Overview
Mabion S.A., based in Konstantynów Łódzki and listed in Warsaw, built a biologics plant to develop and make biosimilar antibodies. Its rituximab biosimilar MabionCD20 was taken through phase 3 comparative trials in diffuse large B-cell lymphoma and rheumatoid arthritis, registered on ClinicalTrials.gov under Mabion as lead sponsor, and the company now also offers contract manufacturing.
Headquarters
Konstantynów Łódzki, PL
Scorecard
All companies#113of 1244 companies, score 47
- approved products +6
- targets +2
- modalities +2
- regions +7
- registry trials +30
1 approved, 0 in phase 3, 0 earlier, 1 targets, 2,033 registry studies. Formula on the scorecards page.
Type
Stage
Public
Website
ApprovedMonoclonal antibody (anti-CD20, chimeric)
Rituximab · Rituxan / MabThera (and biosimilars)
Rituximab was the first antibody ever approved for cancer (1997). It made chemoimmunotherapy the CLL standard for a decade, and biosimilars keep it cheap and everywhere.
Similar pages
- CompanyZhejiang Hisun Pharmaceutical
Shares Biosimilar, Pivotal (registrational) trial, Clinical trial.
- CompanyDenovo Biopharma
Shares Pivotal (registrational) trial, Clinical trial, Diffuse large B-cell lymphoma.
- CompanyAngiocrine Bioscience
Shares Pivotal (registrational) trial, Clinical trial, Diffuse large B-cell lymphoma.
- CompanyPregLem
- CompanyAgennix
- CompanyLisata Therapeutics
- CompanyImmunitor
- CompanyEmergent BioSolutions
cancers
drugs
ApprovedMonoclonal antibody (anti-CD20, chimeric)
Rituximab · Rituxan / MabThera (and biosimilars)